European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading

MT Newswires Live
17 Mar

European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and medical device maker EDAP TMS (EDAP), which climbed 7.6% and 6%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and semiconductor company Sequans Communications (SQNS), which rose 3.3% and 2.9%, respectively.

The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and internet advertising firm Criteo (CRTO), which dropped 2.8% and 1.8%, respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and accommodations booking site trivago (TRVG), which were down 1.7% and 0.5%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Verona Pharma (VRNA) and cruise line operator Carnival (CUK), which advanced 5.9% and 3.1%, respectively. They were followed by software firm Endava (DAVA) and insurance company Prudential (PUK), which were up 3.2% and 1.9%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Trinity Biotech (TRIB), which lost 5.9% and 4.1%, respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Akari Therapeutics (AKTX), which fell 2.7% and 1.8%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10